Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.

Key facts

Study ID

NCT00519662

Run by

Sunesis Pharmaceuticals

People needed

32

Starts

2007-08-01

Expected to finish

2009-03-01

Last updated by the study team

2017-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumor and that is measurable by a scan

You may not qualify if…

• Uncontrolled or untreated central nervous system metastases
• Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1
• Any of the following cardiac conditions:
• History of myocardial infarction, acute coronary syndromes up to 12 weeks before Cycle 1 Day 1
• Class III or IV heart failure up to 6 months before Cycle 1 Day 1
• Baseline heart rate corrected QT interval (QTc)> 450 msec
• History of ventricular arrhythmias up to 6 months before Cycle 1 Day 1
• Use of medications that prolong the QTc interval and are associated with Torsades de Pointe (TdP)
• Previous cancer treatment up to 21 days before first dose
• Any investigational therapy up to 28 days before Cycle 1 Day 1
• Known allergy to cyclodextrins
• Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if all study criteria are met.

Where it is running

• University of Alabama, Birmingham — Birmingham, Alabama, United States
• Stanford University Medical Center — Stanford, California, United States
• University of New Mexico — Albuquerque, New Mexico, United States
• Duke University — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.